Error in Figure
In the original publication [1], there was a mistake in Figure 1 as published. An incorrect version of Figure 1 was included in the publication. This was purely a graphical error and does not affect the model or results. The figure legend for Figure 1 has been updated to rename the internalization rate constant (kint) as the elimination rate constant (kelim), given the definition of internalization which involves endocytosis. The corrected Figure 1 and its legend appear below:
Figure 1.
Schematic representation of (A) T-cell PBPK model and (B) T-cell-TCB-target cell synapse formation model. T-cell transmigration from vascular to extravascular space is indicated by the green arrow. ksyn refers to the zero-order target synthesis rate; kdeg, krec, and kelim refer to the first-order degradation, recycling, and elimination rate contants of the target and the TCB-target complexes, respectively; koff refers to the first-order TCB-target dissociation rate constants; and kon refers to the second-order TCB-target association rate constants.
Text Correction
There was an error in the original publication, where the parameters kelim and kint were incorrectly referenced in Section 2.3.
A correction has been made to Section 2.3, paragraph 3.
“Simulation scenarios for model calibration were defined according to the experimental setup in [9]. The CD3-related parameters (krec, kelim, kon, koff) and HER2 parameters (ksyn, kdeg, kelim, kon, koff) were fitted in a hybrid, stepwise approach, using both manual adjustments and gradient-based parameter identification algorithms (Levenberg–Marquardt) included in the OSP Suite.”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Susilo, M.E.; Schaller, S.; Jiménez-Franco, L.D.; Kulesza, A.; de Witte, W.E.A.; Chen, S.-C.; Boswell, C.A.; Mandikian, D.; Li, C.-C. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.